Literature DB >> 22892552

Lack of antidonor alloantibody does not indicate lack of immune sensitization: studies of graft loss in a haploidentical hematopoietic cell transplantation swine model.

Raimon Duran-Struuck1, Abraham Matar, Rebecca Crepeau, Ashley Gusha, Marian Schenk, Isabel Hanekamp, Vimukthi Pathiraja, Thomas R Spitzer, David H Sachs, Christene A Huang.   

Abstract

Loss of chimerism is an undesirable outcome of allogeneic hematopoietic cell transplantation (HCT) after reduced-intensity conditioning. Understanding the nature of cellular and humoral immune responses to HCT after graft loss could lead to improved retransplantation strategies. We investigated the immunologic responses after graft loss in miniature swine recipients of haploidentical HCT that received reduced-intensity conditioning. After the loss of peripheral blood chimerism, antidonor cellular responses were present without detectable antidonor antibody. Reexposure to donor hematopoietic cells after graft loss induced a sensitized antidonor cellular response. No induced antidonor antibody response could be detected despite evidence of cellular sensitization to donor cells. In contrast, unconditioned animals exposed repeatedly to similar doses of haploidentical donor cells developed antidonor antibody responses. These results could have important implications for the design of treatment strategies to overcome antidonor responses in HCT and improve the outcome of retransplantation after graft loss.
Copyright © 2012 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22892552      PMCID: PMC3575102          DOI: 10.1016/j.bbmt.2012.08.004

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  29 in total

1.  Granulocyte colony-stimulating factor reduces the capacity of blood mononuclear cells to induce graft-versus-host disease: impact on blood progenitor cell transplantation.

Authors:  D Zeng; S Dejbakhsh-Jones; S Strober
Journal:  Blood       Date:  1997-07-01       Impact factor: 22.113

2.  Tolerance and long-lasting peripheral chimerism after allogeneic intestinal transplantation in MGH miniature swine.

Authors:  Yoshinori Ishikawa; Atsushi Hirakata; Adam D Griesemer; Justin Etter; Shannon Moran; Joshua Weiner; Akira Shimizu; Kazuhiko Yamada
Journal:  Transplantation       Date:  2010-02-27       Impact factor: 4.939

3.  Analyses of monoclonal antibodies reacting with porcine CD5: results from the Second International Swine CD Workshop.

Authors:  M D Pescovitz; B K Book; B Aasted; J Dominguez; R Bullido; I Trebichavsky; B Novikov; I Valpotic; M Tomaskovic; J Nielsen; S Arn; D H Sachs; J K Lunney; P C Boyd; J Walker; R Lee; A Saalmüller
Journal:  Vet Immunol Immunopathol       Date:  1998-01-30       Impact factor: 2.046

4.  Induction of donor-type chimerism in murine recipients of bone marrow allografts by different radiation regimens currently used in treatment of leukemia patients.

Authors:  O Salomon; T Lapidot; A Terenzi; I Lubin; I Rabi; Y Reisner
Journal:  Blood       Date:  1990-11-01       Impact factor: 22.113

5.  Allosensitization does not increase the risk of xenoreactivity to alpha1,3-galactosyltransferase gene-knockout miniature swine in patients on transplantation waiting lists.

Authors:  Banny S Wong; Kazuhiko Yamada; Masayoshi Okumi; Joshua Weiner; Patricia E O'Malley; Yau-Lin Tseng; Frank J M F Dor; David K C Cooper; Susan L Saidman; Adam Griesemer; David H Sachs
Journal:  Transplantation       Date:  2006-08-15       Impact factor: 4.939

6.  The detection of donor-directed, HLA-specific alloantibodies in recipients of unrelated hematopoietic cell transplantation is predictive of graft failure.

Authors:  Stephen Spellman; Robert Bray; Sandra Rosen-Bronson; Michael Haagenson; John Klein; Susan Flesch; Cynthia Vierra-Green; Claudio Anasetti
Journal:  Blood       Date:  2010-01-20       Impact factor: 22.113

7.  Induction of tolerance to an allogeneic skin flap transplant in a preclinical large animal model.

Authors:  B M Horner; M A Randolph; R Duran-Struuck; E L Hirsh; K K Ferguson; A G S Teague; P E M Butler; C A Huang
Journal:  Transplant Proc       Date:  2009-03       Impact factor: 1.066

8.  High risk of graft failure in patients with anti-HLA antibodies undergoing haploidentical stem-cell transplantation.

Authors:  Stefan O Ciurea; Marcos de Lima; Pedro Cano; Martin Korbling; Sergio Giralt; Elizabeth J Shpall; Xuemei Wang; Peter F Thall; Richard E Champlin; Marcelo Fernandez-Vina
Journal:  Transplantation       Date:  2009-10-27       Impact factor: 4.939

9.  Strategic nonmyeloablative conditioning: CD154:CD40 costimulatory blockade at primary bone marrow transplantation promotes engraftment for secondary bone marrow transplantation after engraftment failure.

Authors:  Hong Xu; Yiming Huang; Paula M Chilton; Lala-Rukh Hussain; Michael K Tanner; Jun Yan; Suzanne T Ildstad
Journal:  J Immunol       Date:  2008-11-01       Impact factor: 5.422

10.  Analyses of mAb reactive with porcine CD8.

Authors:  A Saalmüller; B Aasted; A Canals; J Dominguez; T Goldman; J K Lunney; S Maurer; M D Pescovitz; R Pospisil; H Salmon
Journal:  Vet Immunol Immunopathol       Date:  1994-10       Impact factor: 2.046

View more
  2 in total

1.  Tandem Orthotopic Living Donor Liver Transplantation Followed by Same Donor Haploidentical Hematopoietic Stem Cell Transplantation for DOCK8 Deficiency.

Authors:  Alexandra F Freeman; Nada Yazigi; Nirali N Shah; David E Kleiner; Mark Parta; Prescott Atkinson; Theo Heller; Steven M Holland; Stuart S Kaufman; Khalid M Khan; Dennis D Hickstein
Journal:  Transplantation       Date:  2019-10       Impact factor: 4.939

2.  Tolerance of Vascularized Islet-Kidney Transplants in Rhesus Monkeys.

Authors:  V Pathiraja; V Villani; M Tasaki; A J Matar; R Duran-Struuck; R Yamada; S G Moran; E S Clayman; J Hanekamp; A Shimizu; D H Sachs; C A Huang; K Yamada
Journal:  Am J Transplant       Date:  2016-08-09       Impact factor: 8.086

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.